Sputnik Technopolice

The company is engaged in the production of medicines and materials used for medical purposes.

History

2023

Opening a research center for the development of import-substituting biologics

The Sputnik Technopolice plant of the R-Pharm group of companies, located in the Technopolice Moscow special economic zone, has opened a research center on its site for the development of import-substituting biologics for the treatment of socially significant diseases. R-Pharm announced this on September 16, 2023.

The total area of ​ ​ the enterprise exceeds 25 thousand square meters, 70% of which are occupied by clean zones where laboratories and production sites are located. The area of ​ ​ the center is about two thousand square meters.

R-Pharm Research Center is equipped with the most up-to-date laboratory-analytical and technological equipment and is designed to develop drugs against cancer, autoimmune and infectious diseases. An important addition is the presence of a pilot production site in the center.

As of September 2023, about 650 employees were employed at the Sputnik Technopolice production facility. The center will create about 75 more new jobs.

The plus of our center is that it is inextricably linked with production. This will significantly reduce the time for transferring the developed technologies to factory capacity, "said Timofey Petrov, General Director of the Sputnik Technopolice plant.

Launch plan for two R&D centers

The resident of the Special Economic Zone (SEZ) Technopolice Moscow"" will launch two research centers (- R&D centers) for the development of biological and chemical medical drugs by the end of 2023. Objects with a total area of ​ ​ more than five thousand square meters will be opened on the basis of biotechnological production in. Russia This was announced on May 31, 2023 by the Deputy Mayor for Moscow Economic Policy and Property and Land Relations. Vladimir Efimov

{{quote 'The Sputnik Technopolice plant, part of the R-Pharm group of companies, received the status of a resident of the capital's SEZ in 2021 and is localized at the Pechatniki site. As of May 2023, 650 people work at the enterprise, the area of ​ ​ which reaches 20 thousand square meters. By the end of 2023, the company plans to launch two research centers inside the production perimeter. They will develop original and import-substituting medicines for the treatment of socially significant diseases. This will additionally create another 120 new jobs, - said Vladimir Efimov. }}

In one of the centers, drugs will be developed by chemical synthesis. In the second - the Center for the Development of Biotechnological Drugs - they will be engaged in the creation of monoclonal antibodies (immune antibodies produced from one plasma cell). The center will be equipped with a pilot production site that allows reproducing the technologies for the production of drugs developed by the R-Pharm group of companies. Then, through the transfer procedure, the technologies will be scaled and transferred to the production facilities of the plant and other sites.

Moscow has signed three offset contracts with R-Pharm for the supply of vital and essential medicines.

Residents of the SEZ "Technopolice Moscow" receive a number of tax benefits, as well as federal and city anti-crisis support. The total volume of investments in the project for the implementation of the plant at the time of construction exceeded 10 billion rubles, which made it possible not only to build buildings in record time and put them into operation, but also to quickly establish the production of drugs, "said Vladislav Ovchinsky, head of the Moscow Investment and Industrial Policy Department.

When developing and launching drugs, the company actively cooperates with research centers of the country - named after Gamaleya, Moscow State University named after Lomonosov, named after Academician Chazov, named after Almazov and many others. As the general director of the SEZ "Technopolice Moscow" Gennady Degtev clarified, about 70 percent of the area of ​ ​ the enterprise located on the basis of the special economic zone is occupied by "clean rooms" with laboratories, production sites for research, development and testing. They are equipped with high-tech equipment, which makes it possible to accelerate the development and introduction of new products into production, increases the availability of innovative and effective drugs for Russian patients.

Monoclonal antibodies obtained at the biotechnology center will be designed to treat cancer and autoimmune diseases, as well as specific infections. As of May 2023, there are not many R&D centers of this level in Russia that would be integrated into production. Our partners from the Asia-Pacific region are actively involved in the project, interaction is developing in several areas at once - scientific, technological and educational, - said the general director of the plant Timofey Petrov.